Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

Johansen, Maria Dinche; Urup, Thomas; Holst, Camilla Bjørnbak; Jarle Christensen, Ib; Grunnet, Kirsten; Lassen, Ulrik; Friis, Søren; Skovgaard Poulsen, Hans

doi:10.6084/m9.figshare.7553207.v1

icnv_a_1544639_sm1720.pdf (371.87 kB)

Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

journal contribution

posted on 2019-01-07, 09:58 authored by Maria Dinche Johansen, Thomas Urup, Camilla Bjørnbak Holst, Ib Jarle Christensen, Kirsten Grunnet, Ulrik Lassen, Søren Friis, Hans Skovgaard Poulsen

Purpose: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.

Methods: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).

Results: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).

Conclusions: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.